ArticleBMJ open respiratory research2025
Treatable moments for smoking cessation in asthma and COPD: a nationwide cohort study.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The right time to quit: patients' experiences of smoking cessation support during COPD hospitalisation.Health psychology and behavioral medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmoking cessation has proven to be the most effective non-pharmacological intervention to tackle poor outcomes in airway diseases. However, there is limited understanding of teachable/treatable moments (specific times when individuals may be particularly open to behavioural change) to support smoking cessation in patients with asthma or chronic obstructive pulmonary disease (COPD). Therefore, we aimed to investigate which health events could create treatable moments for nicotine dependence in these patients.
methodsPatients aged ≥18 years, chronically using medication for obstructive lung diseases between 2017 and 2022 and currently smoking tobacco were identified in Belgian nationwide administrative health data. The impact of potential triggering events on evidence-based cessation attempts (reimbursed tobacco counselling or cessation medication) was investigated by multivariable Cox proportional hazard models. Additional analyses stratified by care setting where cessation was attempted (inpatient vs outpatient), restricted to a first attempt, incident triggering events only and stratified by hospital label (no label, asthma or COPD separately) were conducted.
resultsAmong 94 788 chronic users of pulmonary medication (mean age 61.6 years, 49% female), 12 499 (13.2%) patients attempted smoking cessation. Severe exacerbations (adjusted HR (aHR) 1.82, 95% CI 1.73 to 1.90), use of antidepressants (aHR 1.70, 95% CI 1.64 to 1.76), smoking-related cancer (aHR 1.42, 95% CI 1.33 to 1.52), peripheral vascular disease (aHR 1.42, 95% CI 1.35 to 1.49), admission to critical care (aHR 1.42, 95% CI 1.35 to 1.49), spirometry testing (aHR 1.33, 95% CI 1.27 to 1.38), acute myocardial infarction (aHR 1.32, 95% CI 1.21 to 1.44) and stroke (aHR 1.28, 95% CI 1.18 to 1.38) were associated with a significantly increased likelihood of smoking cessation attempt by more than 25%. All additional analyses confirmed the main findings.
conclusionsIn this nationwide cohort study, we have identified significant treatable moments for smoking cessation beyond established triggering events (eg, stroke and acute myocardial infarction). Exacerbations and spirometry testing were associated with a significantly increased chance of a smoking cessation attempt.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.